A Shortcut to Race Weight

Glucagon-like peptide-1 agonists have helped destigmatize weight issues and been transformational for those struggling with obesity or metabolic dysfunctions, and opened gym doors to previously sidelined individuals.

In a culture increasingly obsessed with optimization and fast-tracking results, it was only a matter of time before athletes began to ponder whether GLP-1s could be repurposed as potent performance enhancers.

On the surface, the significant weight loss resulting from slowed gastric emptying and blunted appetite appears advantageous, especially for disciplines where aesthetics, weight categories, or power-to-weight matters.

But the story becomes far more complicated when looking beyond the scale.

The Endurance Paradox

The blueprint seemed almost too simple. Less body weight. Improved power-to-weight ratio. Faster race times.

But the understanding of endurance performance has evolved beyond the simple pursuit of lightness. 

Elite endurance performance increasingly depends on the ability to fuel more – not less. Where the sport now advocates aggressive carbohydrate intake and gut training, GLP-1s push in the opposite direction.

Weight Loss ≠ Performance

Not all weight loss translates into improved performances.

A meaningful portion of the weight lost with GLP-1s comes from lean muscle mass – critical to support speed and explosiveness, recovery, bone health, and training resilience. 

Resistance training and higher protein intake can only partially help mitigate these losses. And preserving lean mass becomes considerably harder in the context of chronic appetite suppression, particularly among endurance and master athletes who already struggle to consume enough calories and protein.

Fuelling Contradiction

The contradiction extends beyond muscle preservation alone.

By design, GLP-1s blunt appetite and alter food reward signalling. Ad commonly reported gastrointestinal side effects – nausea, vomiting, diarrhea, and gastric discomfort – and the result is at odds with the demands of endurance training, which sets the stage for low-energy availability, dehydration, impaired recovery, and RED-S.

The Durability Issue 

Perhaps the largest unknown surrounding GLP-1 use is its long-term interaction with determinants of athletic longevity. Interactions with training adaptation, bone health, hormonal balance, recovery modalities, and resilience and resistance to injury have not been studied meaningfully in active endurance populations. 

For athletes going for the long game, the data gap is hard to ignore.

Race Weight at a Cost

What’s accelerating GLP-1 adoption in endurance sport is not emerging evidence – it’s the rapid erosion of the barriers that once kept these drugs at the margins.

Low-cost generics, telehealth platforms, daily oral formulations, microdosing strategies, and endorsements from wellness influencers & retired elite athletes are accelerating mainstream adoption – and have every incentive to reframe GLP-1s as endurance tools.

For elite athletes, the temptation may be the strongest – and so are the potential consequences. Operating near physiological ceilings means even subtle disruptions may carry disproportionate effects. Add growing ethical pressure and regulatory environment actively scrutinizing GLP-1 use – being included on WADA’s drug monitoring program – and the risk calculus shifts considerably.

For recreational and masters athletes – arguably the most exposed segment, the case is even weaker. The short-term performance gains are more modest, the lingering long-term unknowns around muscle integrity, bone health, and weight rebound are more consequential. Many more efficient and well-documented performance alternatives may deserve exploring first.

For injured or postpartum athletes, a short and supervised coure of treatment may exceptionally be beneficial in accelerating a return to competition.

An Enduring Question

Even though the physiological trade-offs of GLP1-s don’t translate to durable endurance performance, cultural normalization will inevitably build consumer demand and push some athletes to test the boundaries.

The question now is whether GLP-1s become normalized the way protein, creatine, or supershoes did, or will pharmacological weight manipulation be sanctioned and relegated to Enhanced sports – failing to outweigh the reward of earned performance?